A novel therapeutic modality of inhibiting the glyco-immune checkpoint axis to treat cancer

被引：3
|
作者：
Cao, Lizhi [1 ]
Petrone, Adam [1 ]
Gatlin, Wayne [1 ]
Che, Jenny [1 ]
Das, Abhishek [1 ]
LeBlanc, Robert [1 ]
Siddiquee, Zakir [1 ]
Nerle, Sujata [1 ]
Stanczak, Michal [2 ]
Mayo, Michele [1 ]
Xu, Lihui [1 ]
Normington, Karl [1 ]
Brown, Jeff [1 ]
Yao, Wei [1 ]
Bertozzi, Carolyn [3 ]
Broderick, James [1 ]
Laubli, Heinz [2 ]
Peng, Li [1 ]
机构：
[1] Palleon Pharmaceut, Waltham, MA USA
[2] Univ Basel Hosp, Dept Biomed, Canc Immunol Lab, Basel, Switzerland
[3] Stanford Univ, Dept Chem, Stanford, CA 94305 USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-LB-109
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-109
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Novel immune checkpoint blocker to treat Merkel cell carcinoma
    Galluzzi, Lorenzo
    Kroemer, Guido
    ONCOIMMUNOLOGY, 2017, 6 (06):
  • [32] Monalizumab: inhibiting the novel immune checkpoint NKG2A
    van Hall, Thorbald
    Andre, Pascale
    Horowitz, Amir
    Ruan, Dan Fu
    Borst, Linda
    Zerbib, Robert
    Narni-Mancinelli, Emilie
    van der Burg, Sjoerd H.
    Vivier, Eric
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):
  • [33] Combined Use of Immune Checkpoint Inhibitors and Phytochemicals as a Novel Therapeutic Strategy against Cancer
    Luo, LingJie
    Lin, Caiji
    Wang, Pengfei
    Cao, Danli
    Lin, Yiru
    Wang, Wenxue
    Zhao, Yufan
    Shi, Yongwei
    Gao, Zixiang
    Kang, Xin
    Zhang, Yuanyuan
    Wang, Shuang
    Xu, Mengzhi
    Liu, Huidi
    Liu, Shu-Lin
    Wang, Jiaxing
    JOURNAL OF CANCER, 2023, 14 (12): : 2315 - 2328
  • [34] Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+T cells with high functional and metabolic capacities
    Haas, Quentin
    Markov, Nikita
    Muerner, Lukas
    Rubino, Viviana
    Benjak, Andrej
    Haubitz, Monika
    Baerlocher, Gabriela M.
    Ng, Charlotte K. Y.
    Munz, Christian
    Riether, Carsten
    Ochsenbein, Adrian F.
    Simon, Hans-Uwe
    von Gunten, Stephan
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [35] Economic analyses of immune-checkpoint inhibitors to treat lung cancer
    Vergnenegre, Alain
    Chouaid, Christos
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (03) : 365 - 371
  • [36] The potential of deferasirox as a novel therapeutic modality in gastric cancer
    Jung Hye Choi
    Jung Soon Kim
    Young Woong Won
    Jieun Uhm
    Byeong Bae Park
    Young Yiul Lee
    World Journal of Surgical Oncology, 14
  • [37] The potential of deferasirox as a novel therapeutic modality in gastric cancer
    Choi, Jung Hye
    Kim, Jung Soon
    Won, Young Woong
    Uhm, Jieun
    Park, Byeong Bae
    Lee, Young Yiul
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2016, 14
  • [38] Immune Checkpoint Blockade Enhances Immune Activity of Therapeutic Lung Cancer Vaccine
    Kadam, Pournima
    Singh, Ram P.
    Davoodi, Michael
    Lee, Jay M.
    John, Maie St.
    Sharma, Sherven
    VACCINES, 2020, 8 (04) : 1 - 9
  • [39] Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines
    Oladejo, Mariam
    Paulishak, Wyatt
    Wood, Laurence
    SEMINARS IN CANCER BIOLOGY, 2023, 88 : 81 - 95
  • [40] Translation control of the immune checkpoint in cancer and its therapeutic targeting
    Xu, Yichen
    Poggio, Mauro
    Jin, Hyun Yong
    Shi, Zhen
    Forester, Craig M.
    Wang, Ying
    Stumpf, Craig R.
    Xue, Lingru
    Devericks, Emily
    So, Lomon
    Nguyen, Hao G.
    Griselin, Alice
    Gordan, John D.
    Umetsu, Sarah E.
    Reich, Siegfried H.
    Worland, Stephen T.
    Asthana, Saurabh
    Barna, Maria
    Webster, Kevin R.
    Cunningham, John T.
    Ruggero, Davide
    NATURE MEDICINE, 2019, 25 (02) : 301 - +
12345